BigHat Biosciences Acquires Frugi Biotechnology

Biosynth Acquires Cambridge Research Biochemicals (CRB)

May 9, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a UK-based independent producer of custom peptides and antibody tools. The acquisition expands Biosynth's peptide and antibody capabilities in Europe, adding expertise in complex peptide chemistry, fluorescent dye labelling and custom antibody generation to its existing operations.

Abbott Acquires Bigfoot Biomedical

September 5, 2023

Medical Devices

Abbott has entered a definitive agreement to acquire Bigfoot Biomedical, a developer of smart insulin management systems that integrate continuous glucose monitoring with connected insulin pen caps and a cloud-based provider portal. The acquisition will combine Abbott’s FreeStyle Libre CGM technology with Bigfoot’s dosing-capable pen cap platform to further develop personalized, connected diabetes care solutions; the deal is expected to close in Q3 2023 and financial terms were not disclosed.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

National Resilience Acquires SwiftScale Biologics

December 2, 2021

Biotechnology

National Resilience, Inc. (Resilience) has acquired SwiftScale Biologics, a San Leandro, California–based developer of cell-free protein synthesis (CFPS) technology. Resilience said it will integrate SwiftScale’s CFPS capabilities into its biomanufacturing platforms to accelerate production of complex biologics and next-generation therapies.

Bristol Myers Squibb Acquires Forbius

August 24, 2020

Biotechnology

Bristol Myers Squibb entered into a definitive agreement to acquire Forbius, a clinical-stage protein engineering company, to obtain its isoform‑selective TGF‑beta 1 & 3 program including lead asset AVID200. The deal includes an upfront payment plus potential milestone payments; Forbius' non‑TGF‑beta assets will be transferred to a newly formed private company retained by Forbius' existing shareholders, and the parties expected to close in Q4 2020 subject to customary conditions.

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.